Epidermal growth factor receptor (EGFR) signaling is a known mediator of colorectal carcinogenesis. Studies have focused on the role of EGFR signaling in epithelial cells, although the exact nature of the role of EGFR in colorectal carcinogenesis remains a topic of debate. Here, we present evidence that EGFR signaling in myeloid cells, specifically macrophages, is critical for colon tumorigenesis in the azoxymethane-dextran sodium sulfate (AOM-DSS) model of colitis-associated carcinogenesis (CAC). In a human tissue microarray, colonic macrophages demonstrated robust EGFR activation in the pre-cancerous stages of colitis and dysplasia. Utilizing the AOM-DSS model, mice with a myeloid-specific deletion of Egfr had significantly decreased tumor multiplicity and burden, protection from high-grade dysplasia and significantly reduced colitis. Intriguingly, mice with gastrointestinal epithelial cell-specific Egfr deletion demonstrated no differences in tumorigenesis in the AOM-DSS model. The alterations in tumorigenesis in myeloidspecific Egfr knockout mice were accompanied by decreased macrophage, neutrophil and T-cell infiltration. Pro-tumorigenic M2 macrophage activation was diminished in myeloid-specific Egfr-deficient mice, as marked by decreased Arg1 and Il10 mRNA expression and decreased interleukin (IL)-4, IL10 and IL-13 protein levels. Surprisingly, diminished M1 macrophage activation was also detectable, as marked by significantly reduced Nos2 and Il1b mRNA levels and decreased interferon (IFN)-γ, tumor necrosis factor (TNF)-α and IL-1β protein levels. The alterations in M1 and M2 macrophage activation were confirmed in bone marrowderived macrophages from mice with the myeloid-specific Egfr knockout. The combined effect of restrained M1 and M2 macrophage activation resulted in decreased production of pro-angiogenic factors, CXCL1 and vascular endothelial growth factor (VEGF), and reduced CD31 + blood vessels, which likely contributed to protection from tumorigenesis. These data reveal that EGFR signaling in macrophages, but not in colonic epithelial cells, has a significant role in CAC. EGFR signaling in macrophages may prove to be an effective biomarker of CAC or target for chemoprevention in patients with inflammatory bowel disease.
INTRODUCTION
Colorectal cancer is the third most common cancer globally 1 and accounts for~10% of new cancer diagnoses annually. 1 The risk for colon carcinogenesis is linked to chronic inflammatory states, such as inflammatory bowel disease (IBD). [2] [3] [4] Colitis-associated carcinogenesis (CAC) occurs in 20% of patients diagnosed with IBD, and mortality rates are over 50% in these patients. [2] [3] [4] While mechanisms by which chronic inflammation promotes colonic carcinogenesis are being investigated, [2] [3] [4] unanswered questions remain.
The tumor microenvironment contains various immune cell types, including macrophages. [2] [3] [4] Macrophages represent a heterogeneous subset of innate immune cells with roles in tissue homeostasis, pro-inflammatory and antimicrobial responses, and wound repair, [5] [6] [7] and are of particular interest, given their highly plastic phenotypes that can both promote and inhibit tumorigenesis. 8, 9 Macrophages can alter their function based on the activation program utilized-either M1 or M2 patterns. [5] [6] [7] 10 M1 macrophages are pro-inflammatory, antimicrobial and are thought to be antitumorigenic, although this remains the subject of debate. [5] [6] [7] M2 macrophages are associated with wound healing and have pro-tumorigenic properties. 5, 8, 10 Macrophage activation is dependent upon the colon tumor microenvironment, 9, 11, 12 and pathways that regulate this are incompletely understood. 3, 8 Studies have implicated nuclear factor kappa-light-chainenhancer of activated B cells (NF-κB) signaling [13] [14] [15] and other pathways. 16, 17 We recently demonstrated that epidermal growth factor receptor (EGFR) signaling regulates macrophage activation across various stimuli. 18 EGFR phosphorylation occurs in macrophages and has major effects on expression of both M1 and M2 macrophage activation markers. 18 Importantly, we determined that EGFR signaling occurs in human gastric macrophages from gastritis to gastric adenocarcinoma, 18 leading us to speculate that EGFR signaling in macrophages may also have a role in CAC. EGFR signaling has been most commonly studied within the context of epithelial cell function and has been linked to colorectal cancer initiation and progression. [19] [20] [21] The impact of EGFR protein levels and signaling capacity is an area of ongoing investigation.
by EGFR phosphorylation in macrophages. Myeloid-specific Egfr knockout mice exhibited decreased tumor multiplicity and tumor burden, while epithelial-specific Egfr knockout mice had no differences in phenotype. Loss of Egfr in myeloid cells resulted in decreased M2 and M1 macrophage activation, and decreased angiogenesis. Thus, EGFR signaling in macrophages may represent a potential target for therapeutic intervention in CAC.
RESULTS
EGFR signaling occurs in human colonic macrophages during pre-cancerous stages of CAC The majority of studies related to EGFR signaling during CRC have focused on epithelial cells. [19] [20] [21] [22] [23] Instead, we sought to determine whether human colonic macrophages had detectable levels of phospho-EGFR (pEGFR), a marker of active EGFR signaling, during IBD and associated CAC. We utilized an IBD-associated cancer tissue microarray (TMA) from Vanderbilt University Medical Center, which contained cases of inactive and active ulcerative colitis, dysplasia and colitis-associated carcinoma. 25 pEGFR levels in CD68 + macrophages were detected via immunofluorescence staining ( Figure 1a ) and quantified with the CellProfiler image analysis software (http://www.cellprofiler.com). We observed a low percentage of CD68 + pEGFR + macrophages in inactive colitis that was significantly increased in active colitis and dysplasia (Figures 1b and c) . The percentage of CD68 + pEGFR + macrophages was lower in CAC than in active colitis and dysplasia (Figures 1b and c). The histopathologic diagnosis of inactive colitis indicates an absence of neutrophils, but is typically characterized by expansion of the lamina propria immune cell compartment and relative dropout of the epithelium. As such, no differences in the overall percentage of macrophages were detected between disease groups (Supplementary Figure 1) . These data indicate that pEGFR is present in macrophages during pre-cancerous events associated with colonic inflammation, implying that EGFR signaling in macrophages has an important role in macrophage function during initiation of carcinogenesis. It should be noted that, as expected, pEGFR staining was also abundant in colonic epithelial cells (Figure 1a ).
EGFR signaling in macrophages contributes to AOM-DSS-induced colon tumorigenesis
We next sought to directly determine the role of EGFR signaling in macrophages during colon carcinogenesis. We utilized mice containing myeloid-specific, Egfr deletion (Egfr Δmye ) driven by LysM-Cre, which we have extensively characterized in models of gastric and colonic inflammation, 18 and the appropriate control mice (Egfr fl/fl ). Egfr fl/fl and Egfr Δmye mice were subjected to the azoxymethane-dextran sodium sulfate (AOM-DSS) model of CAC. 27, 28 The AOM-DSS protocol utilized is outlined in Supplementary Figure 2 . No tumors were observed in the AOMonly or DSS-only groups, nor were differences in histologic colitis detectable between genotypes in the DSS-only group (data not shown). The lack of difference in the histologic colitis between genotypes in the DSS-only group is likely due to the prolonged recovery period, resulting in low colitis scores. Only data from the control and AOM-DSS groups are presented herein.
AOM-DSS-treated Egfr Δmye mice had significantly decreased tumor multiplicity and tumor burden, measured as the sum of the area of each tumor, versus AOM-DSS-treated Egfr fl/fl mice (Figures 2a and b) . Further, Egfr Δmye mice were significantly protected from development of high-grade dysplasia, developing a maximum of low-grade dysplasia (Figure 2c ). Representative hematoxylin and eosin-stained images demonstrate the decrease in tumor size and protection from high-grade dysplasia in Egfr Δmye mice (Figure 2d ). The myeloid-specific, Egfr knockout was maintained throughout the entire AOM-DSS protocol, as Figure 3a) . Despite a report indicating that Foxa3 is expressed in hematopoietic progenitor cells, 30 we found no detectable deletion of EGFR in naive splenocytes ( Supplementary Figure 3b) , or bone marrow-derived macrophages (BMmacs; Supplementary Figure 3c EGFR signaling in macrophages enhances the innate immune response in colon tumors The AOM-DSS model utilizes inflammation to drive tumorigenesis. 27, 28, 31 On the basis of decreased histologic colitis, combined with decreased tumor multiplicity and burden in Egfr Δmye mice, we sought to determine the nature of the innate immune response within the tumor microenvironment during AOM-DSS-induced CAC. We assessed 32 cytokines/chemokines via Luminex Multiplex Array. Analytes that were not different between genotypes or undetectable are in Supplementary Table 1 .
The C-C ligand (CCL) chemokines CCL3 (MIP-1α) and CCL4 (MIP-1β) protein levels were significantly decreased in Egfr (Figure 3a ). CCL3 and CCL4 are chemoattractants for innate immune cells, and are produced by macrophages. 32 In addition, levels of the C-X-C ligand (CXCL) chemokines, CXCL9 (MIG) and CXCL10 (IP-10) were diminished in Egfr Δmye tumors (Figure 3a ). CXCL9 and CXCL10 are also primarily produced by macrophages, 33 but induce T-cell infiltration. 34 CCL3, CCL4, CXCL9 and CXCL10 were induced to a similar degree in Egfr fl/fl and Egfr ΔGIepi tumors, and no differences were detected between genotypes (Supplementary Figure 5a) . Taken together, the decreases in CCL3, CCL4, CXCL9 and CXCL10 are indicative of decreased macrophage responses that result in decreased innate and adaptive immune cell infiltration in tumor areas. These significant decreases in macrophage-driven immune responses indicate the essential role of myeloid EGFR in driving CAC.
In addition, Egfr Δmye tumors demonstrated significant differences in cytokine levels (Figures 3b and c) . Leukemia inhibitory factor (LIF), a cytokine with pleiotropic effects on immune function, was decreased in Egfr Δmye tumors (Figure 3b ). LIF protein levels were induced to a similar degree in Egfr fl/fl and Egfr Days post AOM injection ** *** ** *** *** *** *** *** *** *Po 0.05, **P o0.01, ***P o0.001 versus Egfr fl/fl AOM-DSS by two-way ANOVA with Bonferroni post-test (ANOVA significance, P o0.001). In (a, b, f), *Po 0.05, **P o0.01 by one-way ANOVA with Kruskal-Wallis test, followed by Mann-Whitney U-test. In a, b, f and g, n = 7-9 control and 9-12 AOM-DSS-treated mice per genotype.
data show diminished immune cell infiltration in the Egfr
Δmye mice, which is dependent upon EGFR signaling in myeloid cells.
EGFR signaling in macrophages enhances M2 activation in colon tumors Because macrophages were likely the major source of several of the chemokines and cytokines that were significantly reduced in Egfr Δmye tumors, we hypothesized that loss of EGFR led to altered macrophage activation in the tumor microenvironment. M2 macrophages are tumor-associated macrophages and have protumorigenic properties. [5] [6] [7] 10 Thus, the decrease in tumor multiplicity and burden could be due to a diminished M2 macrophage response in Egfr Δmye tumors. Indeed, protein levels of IL-4, IL10 and IL-13, drivers of M2 activation, [5] [6] [7] 10 were significantly upregulated in Egfr fl/fl tumors and decreased in Egfr Δmye tumors (Figure 5a ). Moreover, mRNA levels of the M2 markers, arginase 1 (Arg1) and Il10, were Figure 6a) , nor were differences detectable in Arg1 and Il10 mRNA levels (Supplementary Figure 6b) . IL-13 was detected at very low levels in Egfr fl/fl and Egfr ΔGIepi tumors, but no significant differences were detected (Supplementary Table 2 ). These data correlate with the finding that Egfr fl/fl and Egfr ΔGIepi mice do not have significant differences in the development of CAC.
To confirm that Egfr deletion in myeloid cells resulted in decreased M2 activation, we isolated BMmacs from Egfr fl/fl and Egfr Δmye mice and stimulated them ex vivo with IL-4 and IL10. Markers of M2 macrophage activation were assessed by qRT-PCR. (Figure 5c ). Importantly, Arg1, Chil3 and Il10 mRNA levels were significantly decreased in Egfr Δmye BMmacs (Figure 5c ), consistent with the findings in Egfr Δmye tumors. Together, these data further suggest that EGFR signaling regulates M2 macrophage activation.
To address the mechanism by which macrophage EGFR signaling alters M2 activation, we isolated BMmacs from Egfr fl/fl and Egfr Δmye mice, stimulated them ex vivo with IL-4 and assessed phospho-signal transducer and activator of transcription 6 (STAT6), a known mediator of M2 activation. 40 Egfr Δmye BMmacs exhibited decreased pSTAT6 levels when compared to Egfr fl/fl
BMmacs (Figure 5d). Similarly, AOM-DSS-treated Egfr
Δmye tissues demonstrated reduced pSTAT6 levels in immune cells (Figure 5e ). These data reveal a potential link between EGFR and STAT6 in regulating M2 activation in macrophages.
Macrophage-specific EGFR signaling also augments M1 activation in colon tumors Alterations in M2 macrophage activation in Egfr Δmye mice were not unexpected, given the close association between M2 macrophages and the tumor microenvironment. 8, 9 However, we also observed significant alterations in both the levels of cytokines that induce M1 activation and in M1 markers in Egfr Δmye tumors. Interferon (IFN)-γ and tumor necrosis factor (TNF)-α potently induce M1 macrophage activation. 7 Protein levels of both IFN-γ and TNF-α were significantly upregulated in AOM-DSS-induced tumors in Egfr fl/fl mice and significantly reduced in Egfr Δmye tumors (Figure 6a ), indicative of decreased capacity for M1 macrophage activation. mRNA levels of M1 markers nitric oxide synthase 2 (Nos2) and Il1b were upregulated in Egfr fl/fl tumors, and significantly decreased in Egfr Δmye tumors (Figure 6b ). This decrease in M1 macrophage activation was confirmed at the protein level, as IL-1β protein was also significantly decreased in Egfr Δmye tumors (Figure 6c ). Protein levels of IFN-γ and TNF-α were detectable in Egfr fl/fl and Egfr ΔGIepi tumors, but were not different between genotypes (Supplementary Figure 7a) . mRNA levels of Nos2 and Il1b (Supplementary Figure 7b) , as well as IL-1β protein levels, were upregulated in Egfr fl/fl and Egfr ΔGIepi tumors, but again were not different between genotypes.
To assess the role of EGFR signaling in M1 activation, we isolated BMmacs from Egfr fl/fl and Egfr Δmye mice and stimulated ex vivo with IFN-γ and TNF-α for 24 h. M1 stimulation resulted in robust expression of M1 markers Nos2, Il1b and Tnfa (Figure 6d) . Importantly, mRNA expression of Nos2, Il1b and Tnfa was significantly reduced in Egfr Δmye BMmacs versus Egfr fl/fl BMmacs (Figure 6d ), indicating that EGFR signaling is equally critical for M1 and M2 activation. Intriguingly, M1 activation may have critical role in colon tumorigenesis in this model that is regulated by EGFR signaling.
We have previously demonstrated that EGFR signaling is upstream of NF-κB in macrophages during Helicobacter pylori infection. 18 Moreover, we have reported that there is enhanced nuclear translocation of RELA proto-oncogene, NF-κB subunit (RELA; also known as p65) in two different models of colitis. 41 Thus, we hypothesized that EGFR and NF-κB signaling may regulate M1 activation. We isolated BMmacs from Egfr fl/fl and Egfr Δmye mice, stimulated with IFN-γ and lipopolysaccharide, and assessed phospho-RELA (pRELA) levels. Egfr
Δmye BMmacs had diminished pRELA levels versus Egfr fl/fl BMmacs (Figure 6e ).
Moreover, AOM-DSS-treated Egfr
Δmye tissues had markedly decreased RELA nuclear translocation in lamina propria cells (Figure 6f) . Thus, EGFR signaling activates the NF-κB pathway to regulate M1 activation.
EGFR signaling in macrophages enhances angiogenesis in colon tumors
Angiogenesis is a hallmark of carcinogenesis, 42 and is an essential means by which colon tumor growth is supported. 43, 44 Several cytokines, including vascular endothelial growth factor (VEGF) A and CXCL1 (KC, GRO-α), the murine equivalent of CXCL8 (IL-8), 45 contribute to angiogenesis. [46] [47] [48] [49] M1 macrophages are an important source of CXCL1 26 and both M1 and M2 macrophages are important sources of VEGFA. 50 Based on (i) decreased tumor multiplicity/burden and (ii) decreased M2 and M1 macrophage activation in Egfr Δmye mice, we hypothesized that angiogenesis may be impaired, contributing to diminished tumorigenesis. Egfr
Δmye tumors had decreased mRNA levels of Cxcl1 and Vegfa (Figure 7a ) and altered protein levels of CXCL1 and VEGF (Figure 7b Figure 9b) versus Egfr fl/fl BMmacs. These data confirm that macrophages are a potential source of CXCL1 and VEGF, and that EGFR signaling is critical for expression of these proangiogenic mediators.
To confirm that decreased pro-angiogenic cytokines was accompanied by decreased angiogenesis, we performed immunoperoxidase staining for CD31, a marker of vascular endothelial cells. 51 Representative images demonstrate significantly enhanced angiogenesis in AOM-DSS-treated Egfr fl/fl versus Egfr Δmye mice (Figure 7c) . Notably, angiogenesis in AOM-DSS-treated Egfr Δmye mice was not different than angiogenesis in control Egfr fl/fl and Egfr Δmye mice (Figure 7c ). Both the number of CD31 + blood vessels per case (Figure 7d ) and the total area of CD31 + blood vessels ( Figure 7e ) were significantly decreased in AOM-DSStreated Egfr Δmye mice versus Egfr fl/fl mice. Thus, decreases in pro-angiogenic cytokine production were associated with Ctrl M1
signaling have been performed in epithelial cells. 19, 20, [52] [53] [54] This study outlines an important role for EGFR signaling in macrophages during inflammatory colon tumorigenesis. Herein, we demonstrate that EGFR signaling occurs in human macrophages during pre-cancerous stages of ulcerative colitis and dysplasia, both of which are marked by active inflammation. 3, 4 On the basis of diminished CD68 + pEGFR + cells in CAC, we posit that EGFR signaling in human macrophages may be essential for initiation of inflammation-associated tumorigenesis. Myeloid-specific knockout of Egfr significantly protected mice from tumorigenesis in the AOM-DSS model of CAC. Intriguingly, gastrointestinal epithelial cell-specific knockout of Egfr did not have a phenotype that was significantly different from wild-type mice. Protection from tumorigenesis in Egfr Δmye mice was accompanied by restricted M2 and M1 macrophage activation, which likely contributed to decreased angiogenesis due to less production of pro-angiogenic cytokines and chemokines. These data point to a currently underappreciated role for EGFR signaling in myeloid cells, particularly macrophages, in promoting CAC.
A previous study utilizing Wa5 mice, which carry a dominantnegative allele that impairs EGFR signaling, demonstrated that EGFR signaling inhibited CAC, 55 the opposite of our current result. It should be noted that differences in colon tumorigenesis were only significant when Wa5 mice were crossed with Il10 -/-mice.
55
Il10 -/-mice may have limitations as a model for CAC because effects of the Il10 deletion can be modulated by bacterial infections. 56, 57 The AOM-DSS model is solely dependent upon inflammation as a driver of carcinogenesis. 56, 57 The previous work that demonstrated a protective role for EGFR in colon tumorigenesis also utilized the AOM-DSS model of colon tumorigenesis, but noted no significant differences in tumor multiplicity. 55 Moreover, the Wa5 allele affects all cell types, while our models used herein were myeloid-and gastrointestinal epithelial cell-specific. Taken together, our study provides a strong body of evidence that EGFR signaling in macrophages is a critical component of CAC.
EGFR signaling appears to mediate M1 and M2 macrophage activation. Importantly, we demonstrated via multiple methods in a previously published study that EGFR signaling in macrophages had no effect on apoptosis. 18 Thus, the phenotypes observed are due to alterations in macrophage function, not cell viability. While the finding that decreased M2 activation, which is highly protumorigenic, 8, 10, 52 correlated with decreased tumor multiplicity and burden was not unexpected, the dramatic alteration of M1 activation was somewhat surprising. However, there are potential reasons why M1 activation may have an important role in tumorigenesis. First, as we demonstrated, M1 macrophages are an important source of pro-angiogenic cytokines (VEGF) and chemokines (CXCL1). Second, M1 macrophages are a potent source of NOS2 (as shown herein) and nitric oxide. 6, 7, 18 It has been proposed that nitric oxide, a reactive nitrogen species, promotes colon tumorigenesis by causing DNA mutations and DNA instability. 3, 58 Our work demonstrates that EGFR signaling has a role in promoting both M1 and M2 activation, potentially working synergistically to promote colon tumorigenesis.
In sum, our study outlines a novel role for EGFR signaling in macrophages during CAC. Robust EGFR signaling in human macrophages in stages leading to colitis-associated cancer indicates that macrophage pEGFR may serve as a potential biomarker for CRC risk in colitis patients. Moreover, our previous work showed that TNF-α induced EGFR signaling in macrophages. 18 Thus, one potential benefit of anti-TNF treatment, frequently used in IBD patients, may be suppression of macrophage EGFR signaling. Further studies are imperative to further assess the critical role that EGFR activation has in immune cells in patients at risk for progression to colon cancer.
MATERIALS AND METHODS Reagents
Reagents used for cell culture were from Invitrogen (Carlsbad, CA, USA). Reagents for RNA extraction were from Qiagen (Valencia, CA, USA); those for complementary DNA synthesis and qRT-PCR were from Bio-Rad (Hercules, CA, USA). Murine macrophage colony stimulating factor (M-CSF), IFN-γ, IL-4 and IL10 were from PeproTech (Rocky Hill, NJ, USA). Murine TNF-α was from Thermo Fisher Scientific (Waltham, MA, USA). Azoxymethane and lipopolysaccharide were from SigmaAldrich (St Louis, MO, USA). DSS was from TdB Consultancy (Uppsala, Sweden).
Antibodies
See Supplementary Table 4 for information regarding antibodies.
Cells and culture conditions
BMmacs were isolated and differentiated from murine femurs as described. 18, 59 Red blood cells were lysed in ammonium chloride potassium buffer for 3 min, and 1.25 million cells were differentiated with 20 μg/ml recombinant murine M-CSF for 7 days, with media changes on days 3 and 5. Following differentiation, cells were placed in complete Dulbecco's modified Eagle's medium, supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 25 mM HEPES and 10 mM sodium pyruvate for studies with IFN-γ, TNF-α, IL-4, IL10 or lipopolysaccharide. Stimulation times and doses are indicated in figure legends. Male mice, aged 6-12 weeks, were utilized for all studies. Sample sizes were based on previous AOM-DSS studies from our laboratory. Mice were not removed from the cages into which they were weaned. No other criteria were utilized for selection or randomization. Mice were subjected to the AOM-DSS colon tumorigenesis model. 27, 61 Mice received one intraperitoneal AOM injection (12.5 mg/kg) on day 0, and three doses of 4% DSS in their drinking water on days 5, 26 and 47. The first two cycles of DSS lasted for 5 days, and the third for 4 days. Mice Figure 7 . Egfr Δmye mice demonstrate decreased pro-angiogenic chemokine/cytokine production and angiogenesis during colon tumorigenesis. (a) mRNA levels of the pro-angiogenic chemokine, Cxcl1, and the pro-angiogenic cytokine, Vegfa, were assessed by qRT-PCR from colonic tissues 77 days post-AOM injection. n = 6-8 control tissues and 8-10 tumors with paired non-tumor area per genotype. (b) Protein levels of pro-angiogenic chemokine, CXCL1, and pro-angiogenic cytokine, VEGF, were assessed by Luminex Multiplex Array from colonic tissues 77 days post-AOM injection. n = 5 control tissues and six to nine tumors with paired non-tumor area per genotype. In a, b, *P o0.05, **P o0.01, ***Po 0.001 by one-way ANOVA with Kruskal-Wallis test, followed by Mann-Whitney U-test. were weighed every 7 days from the start of the first DSS cycle and on day 0 to determine the AOM dosage. Mice were killed on day 77.
Animal studies

Rarely, Egfr
Δmye mice developed an enlarged spleen that was not attributable to AOM-DSS treatment. These mice were excluded from further analysis. Tumor multiplicity was determined by visual inspection via dissecting microscope. Tumor burden was determined by the summation of tumor area, assessed by electronic caliper. Histologic colitis and dysplasia were determined by a gastrointestinal pathologist, MKW, in a blinded manner.
Human tissues
The IBD-associated CAC human TMA was utilized as described. 25 Real-time PCR RNA was isolated from cells and tissues as described. 18, 59 Complementary DNA was prepared and PCR was performed as described. 18, 59 See Supplementary Table 3 for primers utilized.
Western blot analysis
Western blot analysis was performed as described. 18, 59 Luminex multiplex array Luminex Multiplex Array was performed as described. 18, 59 Tissues were harvested at time of killing, homogenized via a handheld homogenizer in 300 μl CellLytic MT Cell Lysis Reagent (Sigma) and centrifuged at 14000 g at 4°C twice. All kit instructions were followed in the performance of the Luminex Multiplex Array assay.
Immunofluorescence staining for tEGFR and CD68, and RELA Staining for tEGFR and CD68 in both the TMA and in murine tissues was performed as described, 18 with the following exceptions in murine tissue. An initial blocking step was performed with Background Sniper (Biocare Medical, Concord, CA, USA), followed by incubation with anti-tEGFR. A second blocking step was performed with the Fab fragment of murine IgG for 15 min, followed by 3% goat serum for 15 min, with subsequent incubation with anti-CD68. All other steps were as described. RELA staining and confocal microscopy were performed as described. 41 Immunoperoxidase staining for pEGFR Y1068
Staining for pEGFR in human colonic biopsies was performed as described. 52 Immunoperoxidase staining CD68, MPO and pSTAT6. After overnight heating at 37°C, sections were deparaffinized in xylene and rehydrated in graded alcohols. Sections were incubated with primary antibody overnight at room temperature. After washing, incubation with anti-rabbit horseradish peroxidase-polymer was performed for 30 min. Sections were rinsed and incubated with streptavidin-horseradish peroxidase (Biocare Medical) for 30 min.
CD3, CD45R and CD31. Heat-induced antigen retrieval was performed on the Leica Bond Max using Epitope Retrieval 2 solution for 10 min (CD3, CD31) and 20 min (CD45R). Slides were incubated with primary antibody for 1 h and incubated with secondary antibody for 15 min. CD31 Images were captured using a high-throughput Leica SCN400 Slide Scanner (Leica Biosystems, Wetlzar, Germany) automated digital image system. Tissue samples were mapped using the Ariol Review software (Leica Biosystems). The numbers and areas of CD31 + blood vessels were determined in the Ariol software.
Scoring of CD68, MPO, CD3 and CD45R immunoperoxidase staining 
Purification of colonic epithelial cells
Purification of colonic epithelial cells was performed as described. 18 
Statistical analysis
Data represent mean ± s.e.m. Where data were normally distributed, twotailed Student's t-test was used to determine significance in experiments with only two groups, and one-way analysis of variance with the NewmanKeuls test was used to determine significant differences between multiple test groups. In Figure 4 , the data were square root-transformed to ensure normal distribution prior to statistical analysis. In other cases where data were not normally distributed, a one-way analysis of variance with KruskalWallis test, followed by a Mann-Whitney U-test, was performed. Please see Supplementary Table 5 for all relevant P-values as determined by KruskalWallis test. Statistical analysis of all weight loss curves was performed by two-way analysis of variance with Bonferroni post-test. All statistics were performed in Prism 5.0 (GraphPad Software, San Diego, CA, USA). A P-value of o 0.05 was considered significant.
